Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Acadia Pharmaceuticals develops and sells medicines that treat disorders of the brain and nervous system.
Acadia Pharmaceuticals is a drugmaker that focuses on the brain. Its medicines treat conditions that affect how people think, feel, and sleep, and it sells them mainly to patients in the United States through prescriptions written by doctors.
Its best-known drug is Nuplazid, the first medicine approved in the U.S. to treat hallucinations and delusions tied to Parkinson's disease psychosis, a condition where people with Parkinson's see or believe things that aren't there. Acadia built its whole business on that drug for years. Then it bought a second one: Daybue, a treatment for Rett syndrome, a rare genetic disorder that mostly strikes young girls and robs them of speech and hand control. That deal, worth roughly $140 million upfront, gave the company a second engine so it wasn't leaning on one product. The tricky part of this business is that a drug is only as good as its approval and its label. Nuplazid has faced scrutiny over safety questions and a slow pullback in prescriptions, and Acadia has had to defend the medicine while it ramps up Daybue. Drugmakers like this live and die on clinical trials, patent protection, and whether insurers will pay — not on factories or storefronts. Acadia spends heavily on research and on the sales force that persuades doctors to prescribe its medicines.
So the company's real bet is simple: get more patients onto its two drugs and keep developing new ones for the central nervous system, a field where effective treatments are hard to find and failures are common.
Saved answer · last researched 16 Nov 2026